Zhang Qing, Thomas Sufi M, Lui Vivian Wai Yan, Xi Sichuan, Siegfried Jill M, Fan Huizhou, Smithgall Thomas E, Mills Gordon B, Grandis Jennifer Rubin
Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Proc Natl Acad Sci U S A. 2006 May 2;103(18):6901-6. doi: 10.1073/pnas.0509719103. Epub 2006 Apr 25.
G protein-coupled receptors induce EGF receptor (EGFR) signaling, leading to the proliferation and invasion of cancer cells. Elucidation of the mechanism of EGFR activation by G protein-coupled receptors may identify new signaling paradigms. A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previously described in squamous cell carcinoma of head and neck. In the present study, we demonstrate that TNF-alpha converting enzyme (TACE), a disintegrin and metalloproteinse-17, undergoes a Src-dependent phosphorylation that regulates release of the EGFR ligand amphiregulin upon GRP treatment. Further investigation reveals the phosphatidylinositol 3-kinase (PI3-K) as the intermediate of c-Src and TACE, contributing to their association and TACE phosphorylation. Phosphoinositide-dependent kinase 1 (PDK1), a downstream target of PI3-K, has been identified as the previously undescribed kinase to directly phosphorylate TACE upon GRP treatment. These findings suggest a signaling cascade of GRP-Src-PI3-K-PDK1-TACE-amphiregulin-EGFR with multiple points of interaction, translocation, and phosphorylation. Furthermore, knockdown of PDK1 augmented the antitumor effects of the EGFR inhibitor erlotinib, indicating PDK1 as a therapeutic target to improve the clinical response to EGFR inhibitors.
G蛋白偶联受体可诱导表皮生长因子受体(EGFR)信号传导,进而导致癌细胞增殖和侵袭。阐明G蛋白偶联受体激活EGFR的机制可能会发现新的信号传导模式。先前在头颈部鳞状细胞癌中描述了胃泌素释放肽(GRP)/GRP受体介导的自分泌途径。在本研究中,我们证明肿瘤坏死因子-α转换酶(TACE),一种去整合素和金属蛋白酶-17,会发生Src依赖性磷酸化,该磷酸化在GRP处理后调节EGFR配体双调蛋白的释放。进一步研究发现磷脂酰肌醇3激酶(PI3-K)是c-Src和TACE的中间介质,促进它们的结合以及TACE磷酸化。磷脂酰肌醇依赖性激酶1(PDK1),作为PI3-K的下游靶点,已被确定为在GRP处理后直接磷酸化TACE的先前未描述的激酶。这些发现提示了GRP-Src-PI3-K-PDK1-TACE-双调蛋白-EGFR的信号级联反应,其中存在多个相互作用、易位和磷酸化位点。此外,敲低PDK1增强了EGFR抑制剂厄洛替尼的抗肿瘤作用,表明PDK1可作为改善对EGFR抑制剂临床反应的治疗靶点。